Melina Marmarelis MD (MM)

Panelists discuss how practice improvements and patient resources can be implemented to empower both healthcare providers and ALK+ patients.

Panelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.

Panelists discuss how practice improvements and patient resources can be implemented to empower both health care providers and patients who have ALK-positive disease.

Panelists discuss how patient education strategies support long-term treatment success, adherence, and shared decision-making.

Panelists discuss how they monitor and educate patients on ALK inhibitor side adverse effects while equipping nursing staff to manage toxicities proactively.

Panelists discuss how patient-specific factors, including brain metastases and drug tolerability, influence front-line ALK inhibitor selection.

Panelists discuss how they manage adverse events associated with ALK inhibitors, comparing safety profiles and addressing unique patient concerns.

Panelists discuss how they guide first-line ALK inhibitor selection based on efficacy, tolerability, clinical data, and patient-specific considerations.

Panelists discuss how they prepare patients for ALK inhibitor therapy following a confirmed ALK-positive result.

Panelists discuss how strategic nursing coordination and effective communication support timely and comprehensive biomarker testing for newly diagnosed NSCLC patients.

Panelists discuss how evolving clinical advances and biomarker-driven therapies have transformed treatment practices and outcomes for patients with ALK+ NSCLC.